IPSC - Century Therapeutics Inc
IEX Last Trade
1.76
0.030 1.705%
Share volume: 373,313
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.73
0.03
1.73%
Fundamental analysis
13%
Profitability
0%
Dept financing
12%
Liquidity
75%
Performance
10%
Performance
5 Days
-1.68%
1 Month
-22.81%
3 Months
-42.86%
6 Months
-49.28%
1 Year
-27.87%
2 Year
-82.22%
Key data
Stock price
$1.76
DAY RANGE
$1.66 - N/A
52 WEEK RANGE
$1.28 - $5.51
52 WEEK CHANGE
-$0.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Lalo Flores
Region: US
Website: https://www.centurytx.com/
Employees: 102
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.centurytx.com/
Employees: 102
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.
Recent news